Evidence map›Paper›PMID 31786729›Full record

ArticleThe Psychiatric quarterly2020

Racial Differences in S100b Levels in Persons with Schizophrenia.

Jessica M Gannon, Deanna L Kelly, Abigail Besch, Tanu Thakur, Neil Khurana, Michael R Shurin, Galina V Shurin, Jaspreet S Brar, Daniela Cihakova, Monica V Talor and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in The Psychiatric quarterly, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Schizophrenia and Alarmins.Medicina (Kaunas, Lithuania) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 5 institutions in 2 countries.

Jessica M GannonWestern Psychiatric Hospital, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA. gannonjm@upmc.edu.ORCID 0000-0003-0762-4054
Deanna L KellyMaryland Psychiatric Research Center, University of Maryland, School of Medicine, Baltimore, MD, USA.
Abigail BeschWestern Psychiatric Hospital, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Tanu ThakurInstitute of Human Behavior and Allied Sciences, New Delhi, India.
Neil KhuranaUniversity of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Michael R ShurinDepartment of Pathology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Galina V ShurinDepartment of Pathology, University of Pittsburgh Medical Center, 200 Lothrop Street, Pittsburgh, PA, 15213, USA.
Jaspreet S BrarWestern Psychiatric Hospital, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
Daniela CihakovaDepartment of Pathology, School of Medicine, Johns Hopkins University, Ross 659, 720 Rutland Ave, Baltimore, MD, 21210, USA.
Monica V TalorDepartment of Pathology, School of Medicine, Johns Hopkins University, Ross 659, 720 Rutland Ave, Baltimore, MD, 21210, USA.
K N Roy ChengappaWestern Psychiatric Hospital, University of Pittsburgh Medical Center, 3811 O'Hara Street, Pittsburgh, PA, 15213, USA.
University of Pittsburgh Medical Center · USUniversity of Pittsburgh · USJohns Hopkins University · USInstitute of Human Behaviour and Allied Sciences · INUniversity of Maryland, Baltimore · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The calcium-binding protein S100b is secreted by glial cells in the brain and is also expressed by melanocytes. In nanomolar concentrations, S100b is considered to be a neurotrophic factor, but in micromolar concentrations, it is thought to reflect CNS injury and inflammation. Seen as a potential biomarker in traumatic brain injury, meta-analytic data from several studies report that S100b levels are significantly higher in persons with long standing schizophrenia, but also among first-episode patients compared to healthy control subjects. However, ethnic or racial differences are typically not mentioned when reporting levels of S100b. We assessed serum S100b levels in persons with schizophrenia (n = 136) who were participants in two independent research studies using the same enzyme-linked immunoassay (ELISA). African-American subjects had significantly higher levels of S100b (41.9 pg/ml ± 62.2) than Caucasian subjects (24.9 pg/ml ± 45.4) in the combined dataset (Mann-Whitney U = 1307, p < 0.001), as well as in each independent study. There were no significant differences in S100b levels between men and women. No significant correlations were observed between S100b levels and demographic or clinical variables. These data suggest that ethnicity or race should be given serious consideration when studying and interpreting S100b levels in persons with schizophrenia.

Indexed as

AdultBlack or African AmericanFemaleHumansMaleMiddle AgedS100 Calcium Binding Protein beta SubunitSchizophreniaWhite PeopleS100B protein, humanS100 Calcium Binding Protein beta SubunitAfrican-AmericanCaucasianInflammationRaceS100bSchizophrenia

Identifiers

PMID31786729
OpenAlexW2990349367

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.